Kura OncologyvsEli Lilly and Company

KURA and LLY stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

Kura Oncology (KURA) has a market value of $610M and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, KURA moved -39.0% and LLY +29.1%. Dividend yield: KURA none, LLY 0.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KURA$610M

    LLY$1.27T

    LLY is 2,082 times KURA

  • Revenue, 12 months

    KURA$79M

    LLY$86.5B

    LLY is 1,090 times KURA

  • Net income, 12 months

    KURA-$293M

    LLY$27.6B

  • Operating margin

    KURA-394.3%

    LLY–

  • ROIC

    KURA-192.2%

    LLY35.5%

    227.7 points apart

  • P/E

    KURA–

    LLY46.1

  • Dividend yield

    KURA0.0%

    LLY0.5%

    0.5 points apart

  • 5-year return

    KURA-59.3%

    LLY+439.5%

    498.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KURA-59.3%

LLY+439.5%

20040060020222023202420252026
Returns by period
PeriodKURAWith dividendsLLYWith dividends
1 year since November 19, 2025-39.0%Price -39.0%+29.1%Price +28.3%
3 years since November 20, 2023-27.6%-10.2% a yearPrice -27.6%+130.0%+32.0% a yearPrice +125.4%
5 years since November 19, 2021-59.3%-16.5% a yearPrice -59.3%+439.5%+40.1% a yearPrice +416.7%
10 years since November 21, 2016+25.6%+2.3% a yearPrice +25.6%+1,944.6%+35.2% a yearPrice +1,657.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KURAKura OncologyLLYEli Lilly and Company

Valuation

KURALLY
Valuation
Price$6.91$1,347.11
Market value$610M$1.27T
Enterprise value (EV)–$1.32T
P/E–46.1
P/E, 5-year median–49.9
P/B34.031.6
EV/EBIT–37.8
Free cash flow yield–1.6%

Results and growth

KURALLY
Results and growth
Revenue, 12 months$79M$86.5B
Net income, 12 months-$293M$27.6B
Free cash flow, 12 months-$89M$19.7B
Earnings per share, 12 months-$3.30$30.81
Revenue growth, year on year25.2%44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

KURALLY
Margins and returns on capital
Gross margin–83.6%
Operating margin-394.3%–
Net margin-369.3%31.9%
ROIC-192.2%35.5%
ROE-247.8%88.6%

Balance sheet

KURALLY
Balance sheet
Cash$492M$4.9B
Total debt–$49.5B
Net debt / EBITDA–1.2
Interest cover-227.1×38.9×

Dividends and buybacks

KURALLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KURA or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Kura Oncology or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.27T) is about 2,082.1 times Kura Oncology ($610M), at today's prices.

How did KURA and LLY stock do over the last 10 years?

Since November 21, 2016, KURA's price moved +25.6% and LLY's +1,657.7%. With dividends: KURA +25.6% (+2.3% a year), LLY +1,944.6% (+35.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, KURA or LLY?

The dividend yield at today's price is none for Kura Oncology and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which has the higher profit margins, Kura Oncology or Eli Lilly and Company?

Over the last twelve months, the net margin was -369.3% for Kura Oncology and 31.9% for Eli Lilly and Company, and the operating margin -394.3% and –. Revenue was $79M and $86.5B.

Which is the better investment, Kura Oncology or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.